cvac competition (or absence of)

Came across this post from another forum which I thought some may find of interest. Very favorable for Prima.

Before anyone questions (as someone seems to have done on that forum) whether it is saying that cVac is no good (e.g. there was no survival benefit), that statement is to do with Avastin (being no good). If you remove the following text ... ...then it reads correctly. It seems to have been pasted in by accident.

"Prima BioMed Ltd, Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889"


[As per the company update today. Good to see some detail on potential competition, and the lack of a real challenger to Cvac.

Competition

The existing treatments for ovarian cancer are surgery, chemotherapy, and radiation therapy. In some cases two or even all three of these treatments are used. These approaches are designed to debulk the tumour and then eradicate any remaining tumour cells. The key chemotherapeutic drugs used are platinum-based drugs such as cisplatin or carboplatin, and taxane drugs, such as paclitaxel. These drugs are all off patent and are readily available at relatively low cost. In the event of relapse, the patient is generally subjected to subsequent courses of chemotherapy and/or radiation therapy.
There are several products in clinical development for the treatment of ovarian cancer. These include new chemotherapeutic agents and products targeting the immune system such as vaccines and antibody therapies. Antibodies are forms of passive immunotherapy and offer greatest benefit when they influence tumour growth. Avastin, an antibody already approved for the treatment of colon cancer has recently completed a study in ovarian cancer patients in remission. There was no survival benefit of using the
Prima BioMed Ltd, Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889
drug and remission was prolonged on average just over three months. There is one competitive dendritic cell based technology under development by Dendreon that has completed a Phase I clinical trial targeting her-2/neu for breast cancer.
Several of the immunological approaches under development may compete with CvacTM as immunological approaches are generally aimed at preventing relapse and metastases. New cytotoxic compounds are unlikely to compete with CvacTM as they are generally used as acute first and second line therapeutic agents. These products are also likely to have significant side effects associated with them consistent with existing chemotherapeutic agents.

Any insight on profit margins for this type of drug. They were talking up to $900million target revenue - what could this mean for the SP? ]